HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 296/2/H462    most recent 00733.2008v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takenaka, H. Articles by Kadomatsu, K. Search for Related Content PubMed PubMed Citation Articles by Takenaka, H. Articles by Kadomatsu, K.

Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction

Departments of ¹Cardiothoracic Surgery, ²Cardiology, and ³Biochemistry, Nagoya University Graduate School of Medicine; ⁴Department of Cardiovascular Research, Research Institute of Environmental Medicine, Nagoya University, Nagoya; and ⁵Cell Signals Incorporated, Yokohama, Japan

Submitted 15 July 2008 ; accepted in final form 18 November 2008

Cardiac remodeling is thought to be the major cause of chronic heart dysfunction after myocardial infarction (MI). However, molecules involved in this process have not been thoroughly elucidated. In this study we investigated the long-term effects of the growth factor midkine (MK) in cardiac remodeling after MI. MI was produced by ligation of the left coronary artery. MK expression was progressively increased after MI in wild-type mice, and MK-deficient mice showed a higher mortality. Exogenous MK improved survival and ameliorated left ventricular dysfunction and fibrosis not only of MK-deficient mice but also of wild-type mice. Angiogenesis in the peri-infarct zone was also enhanced. These in vivo changes induced by exogenous MK were associated with the activation of phosphatidylinositol 3-kinase (PI3K)/Akt and MAPKs (ERK, p38) and the expression of syndecans in the left ventricular tissue. In vitro experiments using human umbilical vein endothelial cells confirmed the potent angiogenic action of MK via the PI3K/Akt pathway. These results suggest that MK prevents the cardiac remodeling after MI and improves the survival most likely through an enhancement of angiogenesis. MK application could be a new therapeutic strategy for the treatment of ischemic heart failure.

growth factor

This article has been cited by other articles:

				J. Floege and S. Uhlig Kidney calling lung and call back: how organs talk to each other Nephrol. Dial. Transplant., September 15, 2009; (2009) gfp464v1. [Full Text] [PDF]